< Return back to Press Releases
Patrik Sebastian Jeanmonod has been appointed
Vice President Finance of Bridge Laboratories, Inc.
June 12, 2006 - San Francisco, CA
Bridge Laboratories announced today that Mr. Patrik Sebastian Jeanmonod has been appointed Vice President Finance effective June 9th, 2006. Mr. Jeanmonod areas of responsibility will include corporate finance, financial planning and analysis, treasury and taxes.
Prior to joining Bridge, Patrik served as VP Global Finance for the Covance Central Laboratory division with laboratory operations in Indianapolis USA, Geneva Switzerland, Cape Town South Africa, Australia and Singapore. His management responsibilities included general accounting, financial planning and analysis, legal and (CFS) client financial services. He also implemented adherence to the Sarbanes-Oxley Act of 2002.
Mr. Jeanmonod played a key role in globalizing the Finance group in the Central Laboratory division. Born in Geneva, Switzerland, Patrik Sebastian Jeanmonod has a Master's Degree in Commercial and Industrial Sciences from the University of Geneva and an Entrepreneurship certificate from the University of Neuchatel.
Patrik brings a wealth of international experience; prior to joining Covance he held a variety of key management positions at Chopard, a Swiss luxury goods company, Megavoice offering international communication options. Mr. Jeanmonod also served as the controller for Bergerco International, division of ConAgra. Mr. Jeanmonod began his career as financial analyst with the United European Bank in Geneva, Switzerland.
Bridge Laboratories is a US-headquartered preclinical contract research organization (CRO) which focuses on providing FDA compliant drug development services in Asia for US and EU based clients. Bridge has been backed by top tier US, Taiwan and Singapore venture capital and investment banking firms and has recently raised over $26M in private equity capital for services development and expansion. Bridge's current capabilities include nearly all aspects of preclinical discovery and development, including, PK and ADME, safety pharmacology, and GLP compliant toxicology in all major testing species. Bridge also provides services for US IND compilation and submission and pre-IND meetings.
About Pharmaron
Founded in 2003, Pharmaron is a leading pharmaceutical and biotechnology drug R&D CRO, with operations in China and the United States. Clients include pharmaceutical, biotechnology, academic and government organizations. As a research-driven and customer-focused company, Pharmaron provides a broad, integrated portfolio of laboratory and manufacturing services from drug discovery to IND submission. These services are designed to help its global partners improve the success of research and shorten the time of development cost effectively in discovering and developing drugs. For more information about Pharmaron, please visit http://www.pharmaron.com.
|
